How Medtech Founders Should Sequence a Medical Device Pricing Strategy

A medical device pricing strategy has to be engineered before the first sale. Beyond revenue, pricing is how a company signals market maturity and acquirer readiness.

Key Takeaways

• A medical device pricing strategy signals market maturity to acquirers and investors long before it generates meaningful revenue.
• Sayenza Bio's Derek Banyard described two pricing models for one platform, a capital purchase for busy plastic surgeons and a free device with a consumable subscription for practices that don't need the full machine.
• Luminare's Sarma Velamuri, MD says the company prices so a hospital breaks even within the first three to five months, even when customers say it isn't charging enough.
• Payers decide coverage, and Josh Makower says the process is not as transparent or predictable as the industry would like.
• A clean, scalable pricing model does more than protect revenue. It removes the friction an acquirer would otherwise have to underwrite themselves.

Why Pricing Has to Be Engineered Before Revenue Even Starts

Pricing has to be engineered before revenue starts, and a lot of founders skip that step. Skipping it leaves a company without a clean reimbursement path or a scalable gross margin story when investors and acquirers start looking.

I covered this on an episode about how mini strategics are winning medtech exits:

"Engineer your pricing and reimbursement economics early. This sounds like it's common sense, but a lot of people don't do this. Pricing isn't really just about revenue. It's essentially how you signal market maturity and acquire readiness."

A clean reimbursement path or a scalable gross margin story does two jobs at once. It wins investors in the near term, and it removes friction for a future acquirer who will eventually have to underwrite that same economic model.

Founders who wait until a deal is on the table to think about pricing architecture are building that pricing architecture in front of the exact audience judging whether the company understands its own market.

How Segment-Based Pricing Sequences Around Different Buyers

A single price point rarely fits every buyer in a medtech category. Sequencing pricing well means matching the model to how each segment buys instead of forcing one structure onto every customer.

I interviewed Derek Banyard, founder of Sayenza Bio, on an episode about regenerative medicine. He described how the company is thinking about pricing:

"For the busy plastic surgeon who's doing everything, he's doing mommy makeovers and doing a lot of lipo and a lot of volumization, that surgeon is going to pay an upfront capital cost for the platform of about $50,000, and then they're going to pay anywhere from $400 to $600 per consumable."

That's one segment. For pain and orthopedic practices, the company is considering a free device with a consumable subscription, because it doesn't want the platform's price to be an impediment to adoption.

Two segments, two pricing models, one platform. That decision gets made at the design stage, before a sales team is fielding objections it has no answer for.

Why Pricing Should Be Sequenced to a Customer's Payback Window

Pricing that ignores how fast a buyer sees return is built around the seller's convenience instead of the buyer's adoption curve.

I interviewed Sarma Velamuri, MD, of Luminare, on an episode about sepsis in hospitals. Velamuri described how the company prices:

"What we want to show our customers is a break-even within the first three to five months."

Velamuri says customers sometimes tell the company it isn't charging enough, and the company knows. Customer outcomes and margins come first, because the company has no business if its hospital customers stop existing.

That is a deliberate pricing choice. The company sets price against the customer's break-even first, and a per-patient, per-day model keeps the bill predictable for a hospital budgeting a year ahead.

What Happens When Founders Never Take Control of Pricing

Founders who treat pricing as something to figure out later leave the decision to the payer. Once that happens, the company negotiates from a position someone else set.

I interviewed Josh Makower on an episode about the FDA, the AMA and medtech innovation. He explained who decides coverage:

"Obviously you could have a code, but if your insurer says, 'Hey, we don't cover that,' you're out of luck. That decision is made by the payer, could be CMS, could be a private company.

They have to decide whether they're going to pay or not. The process by which they go about deciding that today is not as transparent or predictable as we would like."

The payer, not the company, makes that call. That is why engineering pricing and reimbursement economics early matters, because the company should arrive with its economics already worked out.

A founder who sequences pricing early, segment by segment, tied to the buyer's own payback math, arrives at that negotiation prepared. A founder who waits arrives without a position.

What This Means for Medtech Founders

In my experience working with medtech founders, pricing gets left until late even though it sounds like common sense to engineer it early. That ordering is a mistake.

Pricing set early does three jobs: it signals market maturity to investors, it matches the model to how each buyer segment pays, and it protects the company's negotiating position for years.

The founders who get this right sequence pricing alongside product development instead of after it. They design segment-specific models before a sales team ever needs one, and they price to the buyer's payback window instead of an internal margin target.

Reimbursement and pricing are some of the first things a market reads to judge whether a company understands the category it is trying to sell into.

Frequently Asked Questions

When Should a Medtech Founder Set Their Pricing Strategy?

Pricing should be engineered alongside product development, well before the first commercial sale. Founders who wait until launch to think about pricing leave no room to build segment-specific models before a sales team needs them.

Engineering pricing and reimbursement economics early also gives investors a clean reimbursement path or a scalable gross margin story to evaluate.

Should a Medical Device Company Price the Same Way for Every Customer?

Not necessarily. Different buyer segments have different capital tolerances and volume patterns.

Sayenza Bio, for example, is considering a capital purchase of about $50,000 plus per-consumable fees for busy plastic surgeons, and a free device with a consumable subscription for practices that don't need the full machine, all on one platform.

Why Does Medtech Reimbursement Sequencing Matter to an Acquirer as Well as Investors?

A clean, scalable pricing and reimbursement model removes friction an acquirer would otherwise have to solve themselves after a deal closes. Acquirers read pricing discipline as a signal that a company understands its own market.

When a company's economics map cleanly into a strategic's existing structure, it is presenting an asset instead of pitching.

Where to Go From Here

If you're doing this yourself. Read the medtech commercialization strategy breakdown to see where pricing fits inside the broader sequence of category, messaging, and go-to-market.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. For founders about to set pricing, the audit checks whether the model matches how buyers pay before it ships.

Listen to the Full Conversations

• $100B Exit Fix: How Mini Strategics Are Winning
• Why Fat Is Liquid Gold in Regenerative Medicine With Sayenza Bio Founder Derek Banyard
• Why Luminare Wants to Make Sepsis the #2 Killer in Hospitals With Sarma Velamuri, MD
• Is the FDA and AMA Killing Medtech Innovation? Josh Makower Reveals the System Fix

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialisation strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.